TalkMed Continues Preliminary Discussions Over Acquisition
TalkMed (SGX:5G3) said that the discussions unrelated persons for the acquisition of a stake in the company are still in a preliminary stage, according to a filing with the Singapore Exchange on Tuesd
TalkMed's Subsidiary Enters Sale and Purchase Agreement to Dispose Shares in Unit
TalkMed (SGX:5G3) 30% associate company, Hong Kong Integrated Oncology Centre Holdings (HKH) entered into a sale and purchase agreement to dispose off its interest in shares of Hong Kong Integrated On
TalkMed in Preliminary Acquisition Talks
TalkMed (SGX:5G3) said that discussions with a group of interested persons are ongoing for a proposed acquisition of a stake in the company, a filing with the Singapore Exchange said on Thursday. The
TalkMed Group Cautions Shareholders Amid Acquisition Talks
Investors in TalkMed Group (SGX:5G3) Have Unfortunately Lost 5.0% Over the Last Five Years
TalkMed Group Hosts 11th Annual General Meeting
TalkMed Reaches Final Settlement in Mediation Related to Claims in Stem Med Stake Disposal
TalkMed (SGX:5G3) has agreed to a full and final settlement after attending mediation in a legal proceeding related to the disposal of its entire stake in Stem Med to Edge Capital Fund SP2 (ECF), acco
TalkMed Group Settles High Court Litigation
Here's Why We Think TalkMed Group (SGX:5G3) Might Deserve Your Attention Today
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage
TalkMed Group Signals Potential Acquisition Talks
Is TalkMed Group Limited's (SGX:5G3) Stock Price Struggling As A Result Of Its Mixed Financials?
TalkMed Group Awards 1.1 Million New Shares
TalkMed Group (SGX:5G3) allotted and issued 1.1 million ordinary shares, pursuant to its performance share plan, according to a company filing on the Singapore Exchange on Wednesday. Following the iss
TalkMed's H2 Attributable Profit Falls on Wider Impairment Loss
TalkMed Group (SGX:5G3) registered a lower profit attributable to owners for the second half of 2023 despite higher revenue after impairment losses widened. The cancer care services provider's attribu
TalkMed Group Grants Nearly 8 Million Share Awards Under Performance Share Plan
Healthcare services provider TalkMed Group (SGX:5G3) granted 7,692,000 share awards to eligible employees of the group under its performance share plan on Tuesday. The awards will vest progressively w
TalkMed Group (SGX:5G3) Investors Are Sitting on a Loss of 20% If They Invested Five Years Ago
TalkMed Group Issues New Shares Upon Vesting of Share Awards
TalkMed Group (SGX:5G3) allotted and issued 499,999 new ordinary shares on Monday upon vesting of share awards that were granted on Oct. 15, 2021 under the company's performance share plan. Following
With EPS Growth And More, TalkMed Group (SGX:5G3) Makes An Interesting Case
Singapore Stocks Track Global Gains to Close Higher; Delfi Shares Jump 3% on Higher H1 Profit, Revenue
Singapore's Straits Times Index opened some eight points higher on Tuesday and closed marginally in green at the end of the session, tracking overnight gains in the US and Europe. During the day, the
TalkMed Group's Attributable Profit Zooms 18% in H1
TalkMed Group (SGX:5G3) logged a profit attributable to the owners of SG$14.3 million in the first half of the year, up 17.7% from SG$12.1 million a year ago. Earnings per share jumped to SG$0.0107 du
TalkMed Group Establishes New Subsidiary for Cell, Gene Therapy
TalkMed Group (SGX:5G3) has teamed up with StemCord to establish a majority-owned subsidiary named BioCell Innovations. BioCell Innovations will be involved in the development of novel processing plat
No Data